Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: A cohort study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 2, 2010, Pages 160-165

  Ehrt, Uwe ^a   Broich, Karl ^b   Larsen, Jan Petter ^a   Ballard, Clive ^c   Aarsland, Dag ^a,d  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b Federal Institute for Drugs and Medical Devices   (Germany)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANXIOLYTIC AGENT; BENZATROPINE; CARDIOVASCULAR AGENT; CITALOPRAM; CLOZAPINE; DIAZEPAM; DIGITOXIN; DOXEPIN; EMEPRONIUM; FLUOXETINE; FLUVOXAMINE; FUROSEMIDE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; ORPHENADRINE; PAROXETINE; PHENOBARBITAL; PROMAZINE; QUETIAPINE; SEDATIVE AGENT; THIORIDAZINE; TRIHEXYPHENIDYL; TRIMIPRAMINE; UNINDEXED DRUG;

AGED; ANTICHOLINERGIC EFFECT; ARTICLE; AWARENESS; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION;

AGED; ANTIDEPRESSIVE AGENTS; BRAIN; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PREVALENCE; SEVERITY OF ILLNESS INDEX;

EID: 76549126343     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.186239     Document Type: Article

References (37)

1. Buter TC, van den Hout A, Matthews FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008;70:1017-22.
2. Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407-11.
3. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry 2007;78:641-3.
4. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999;15:15-28.
5. Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008;56:1333-41.
6. Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006;332:455-9.
7. Tune LE. Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry 2000;5:149-53.
8. Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry 2001;62(21 Suppl):11-4.
9. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23:183-9; [quiz 313].
10. Fenelon G. Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 2008;13:18-25.
11. Artero S, Ancelin ML, Portet F, et al. Risk profiles for mild cognitive impairment and progression to dementia are gender specific. J Neurol Neurosurg Psychiatry 2008;79:979-84.
12. McShane R, Keene J, Gedling K, et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 1997;314:266-70.
13. Mulsant BH, Gharabawi GM, Bossie CA, et al. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry 2004;65:1708-14.
14. Tandberg E, Larsen JP, Aarsland D, et al. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996;53:175-9.
15. Larsen JP, Dupont E, Tandberg E. Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994;89:242-51.
16. Aarsland D, Perry R, Brown A, et al. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58:773-6.
17. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004;61:1906- 11.
18. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state.' A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
19. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
20. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
21. Aarsland D, Larsen JP, Reinvang I, et al. Effects of cholinergic blockade on language in healthy young women. Implications for the cholinergic hypothesis in dementia of the Alzheimer type. Brain 1994;117:137784.
22. Sperling R, Greve D, Dale A, et al. Functional MRI detection of pharmacologically induced memory impairment. Proc Natl Acad Sci U S A 2002;99:45560.
23. Ziabreva I, Perry E, Perry R, et al. Altered neurogenesis in Alzheimer's disease. J Psychosom Res 2006;61:311-6.
24. Rubio A, Perez M, Avila J. Acetylcholine receptors and tau phosphorylation. Curr Mol Med 2006;6:423-8.
25. Menza M, Defronzo Dobkin R, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2008;72:886-92.
26. Claassen JA, Jansen RW. Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergicvascular hypothesis. J Gerontol A Biol Sci Med Sci 2006;61:267-71.
27. Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003;54:235-8.
28. Ballard CG, Chalmers KA, Todd C, et al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology 2007;68:1726-9.
29. Ballard CG, Perry RH, McKeith IG, et al. Neuroleptics are associated with more severe tangle pathology in dementia with Lewy bodies. Int J Geriatr Psychiatry 2005;20:872-5.
30. Leng Y, Chase TN, Bennett MC. Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm. J Biol Chem 2001;276:28212-8.
31. Starkstein SE, Bolduc PL, Mayberg HS, et al. Cognitive impairments and depression in Parkinson's disease: a follow up study. J Neurol Neurosurg Psychiatry 1990;53:597-602.
32. Llebaria G, Pagonabarraga J, Kulisevsky J, et al. Cut-off score of the mattis dementia rating scale for screening dementia in Parkinson's disease. Mov Disord 2008;23:1546-50.
33. Han L, McCusker J, Cole M, et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001;161:1099-105.
34. Aizenberg D, Sigler M, Weizman A, et al. Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case-control study. Int Psychogeriatr 2002;14:307-10.
35. Tollefson GD, Montague-Clouse J, Lancaster SP. The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population. J Neuropsychiatry Clin Neurosci 1991;3:314-9.
36. Tune L, Carr S, Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992;149:1393-4.
37. Thomas C, Hestermann U, Kopitz J, et al. Serum anticholinergic activity and cerebral cholinergic dysfunction: an EEG Study in frail elderly with and without delirium. BMC Neurosci 2008;9:86.